by Peter Ciszewski | Sep 14, 2021
Clete A. Kushida, MD, PhD, Neurologist and Division Chief and Medical Director of Stanford Sleep Medicine Center, explains how sleep is measured in clinical trials such as the REST-ON study, a double-blind, randomized, placebo-controlled phase 3 trial assessing...
by Peter Ciszewski | Sep 10, 2021
Saad Usmani, MD, FACP, Division Chief of Plasma Cell Disorders and Director of Clinical Research in Hematological Malignancies at Levine Cancer Institute, discusses follow-up data from the CARTITUDE-1 trial presented at ASCO 2021. Multiple myeloma is a blood...
by Peter Ciszewski | Sep 9, 2021
Sima Rozati, MD, Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine, discusses current treatment options for cutaneous T-cell lymphoma (CTCL). CTCL belongs to the non-Hodgkin lymphoma family as a rare group of malignancies....
by Peter Ciszewski | Sep 2, 2021
Richard Lafayette, MD, FACP, Director of the Stanford Glomerular Disease Center, Editor-in-Chief of ASN Kidney News, and Rheumatologist at Stanford Health Care, describes the patient population for immunoglobulin A (IgA) nephropathy. IgA nephropathy, also...
by Peter Ciszewski | Sep 1, 2021
Mary Dunkle, Senior Advisor for the National Organization for Rare Disorders (NORD), discusses the upcoming NORD Breakthrough Summit 2021 being held October 18-19, 2021. As Ms. Dunkle explains, the summit is one of the most important conferences in rare...
